

REMARKS/ARGUMENTS***Information Disclosure Statement***

As requested, enclosed are copies of missing references B1-B3, B46 and B48. Applicants respectfully request the Examiner review these references and initial the attached PTO-1449.

Amendment of Claims

Claim 19 is hereby amended as helpfully suggested in the Office Action. No claims have been added or canceled. Claim 19 as amended is clearly supported in the specification at Table 6 (pages 40-41).

Claim 20 is hereby amended to depend from Claim 19. In the absence of this amendment, Claim 20 would be identical to Claim 7. Claim 20 as amended is clearly supported in the specification at page 13, lines 11-13; Figure 4; Table 6 (pages 40-41); and Examples 1 and 2 (pages 86-107).

Correction of Inventorship

The Applicants wish to correct the inventorship based on the claims currently in prosecution. An Amendment and Petition to Correct Inventorship Under 37 CFR 1.48(b) is hereby enclosed.


Conclusion

The Commissioner is hereby authorized to charge any filing fees that may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc.

In view of the foregoing amendments and remarks, the Applicants respectfully request entry of all amendments, removal of any objections or rejections, and allowance of all claims.

Respectfully submitted,

Please send all future correspondence to:
US Patent Operations/TJG
Dept. 4300, M/S 28-2-C
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799


Timothy J. Gaul
Attorney/Agent for Applicants
Registration No.: 33,111
Phone: (805) 447-2688
Date: October 26, 2006